Category
Nausea, constipation and fatigue are common on Ozempic, Wegovy, Mounjaro and Zepbound, and usually fade. A small number of side effects are serious. A plain-language guide to what to expect, how to manage it, and when to call a doctor.
Several blood tests are now FDA-cleared to help detect the brain changes of Alzheimer’s, replacing many PET scans and spinal taps. A plain-language guide to what they measure, what results mean, who they are for and what they cost.
Immunotherapy helps the immune system fight cancer, and for some patients it produces remissions that last years. A plain-language guide to checkpoint inhibitors and other types, who benefits, and the side effects that can appear months later.
Lupus can affect almost any organ, looks different in every patient, and is often diagnosed late. A plain-language guide to the disease, the kidney complication doctors watch for, today’s treatments and why some are so expensive.
In its first global guideline on childhood obesity, the WHO says medicines such as GLP-1 drugs should be considered only for adolescents, and only after a supervised lifestyle program has not worked. No drugs or surgery for children nine and under.
Gene therapy adds a working gene; gene editing rewrites the one you have. A plain-language guide to how each works, what is already approved, what they cost, and the risks that still limit them.
It is one of the most common autoimmune diseases, and one of the slowest to be diagnosed. A plain-language guide to what Sjögren’s is, how it is found, how it is managed today, and the new drugs in late-stage trials.
CAR-T turns a patient’s own immune cells into a living drug. It has transformed some blood cancers and is now being tested in lupus and multiple sclerosis. A plain-language guide to the process, the risks and what comes next.
From rheumatoid arthritis to eczema and alopecia, JAK inhibitors are among the most versatile drugs in immunology. A plain-language guide to how they work, the main ones, and why they carry a boxed warning.
Both remove amyloid from the brain and modestly slow early Alzheimer’s. They differ in how they are given, how long treatment lasts, the risk of brain swelling, and cost — differences that matter when choosing.
TrumpRx.gov lists discounted cash prices for brand-name drugs, including GLP-1s such as Zepbound, Wegovy and Ozempic. Here is how it works, what the prices are, and when it is — and isn’t — the cheapest option.
Lilly’s triple-hormone drug produced some of the largest weight loss ever seen in obesity trials. It isn’t approved yet — and a fast-growing online market selling it as a “research peptide” carries real dangers.
Both promise to spot signs of dozens of cancers from a single blood draw, and neither is FDA-approved yet. Here is how they differ on what they measure, how often they raise false alarms, what happens after a positive result, and cost.
Both are once-daily GLP-1 tablets for weight loss, and both start at $149 a month. But they are very different drugs — and the differences in how you take them, how much weight people lost, and what higher doses cost are worth knowing.
A plain-language guide to Berger’s disease — what goes wrong in the kidneys, how it is found, why it is more serious than once thought, and how a wave of new drugs has changed treatment.
A new report finds the American cancer death rate has dropped by more than a third over three decades — the result of less smoking, earlier detection and better treatment — even as new challenges loom.
With more than 3,000 dead in the fastest-spreading Ebola outbreak on record, the DRC has begun giving frontline health workers an existing vaccine — used compassionately, because it wasn’t designed for this strain.
A concentrated compound called 7-OH — barely present in the natural kratom leaf but abundant in new commercial products — is driving opioid-like dependence and harsh withdrawal, clinics say.
Pooling 69 trials and 150,000-plus adults, researchers found routine calcium and vitamin D supplements did little to prevent fractures or falls — with important exceptions for people who are deficient or have osteoporosis.
Olivia and Tom Walton have committed an initial $100M to Healthy Moms, Healthy Babies America. The money is small next to the problem — which is exactly why it is structured as matching capital.
Bundibugyo virus, a lesser-known cousin of Ebola, has caused its largest outbreak on record in Central Africa — and there’s no licensed vaccine or treatment for it.
A new electronic artificial urinary sphincter lets men restore bladder control at the push of a key-fob button — a potential upgrade over devices that require an awkward manual squeeze. Early results are promising, but the study is tiny.
IUD placement can hurt — and patients have long said so. A double-blind randomized trial found a lidocaine paracervical block reduced pain, especially for those who’ve never given birth.
The faith’s governing body will now permit members to accept the major blood components and blood-derived products, while maintaining its prohibition on whole-blood transfusions.
A major review confirms that exercise-based cardiac rehabilitation delivers lasting benefits after heart disease. The bigger problem, a companion review finds, is that most eligible patients never take part.
Removing the fallopian tubes during another planned surgery can sharply cut the risk of the deadliest ovarian cancer. The evidence is strong; the challenge is making sure eligible people are actually offered it.
Wernicke encephalopathy, caused by a lack of vitamin B1, can be reversed if caught early — but doctors frequently miss it because the “classic” warning signs usually don’t all show up.
New evidence suggests that for people with one or two small, low-risk polyps removed, waiting longer between follow-up colonoscopies is safe — sparing patients procedures many are getting too often.
Pooling 139 trials, researchers found the most effective drug-free treatments for knee osteoarthritis were surprisingly simple: knee braces, water-based therapy and regular exercise — while a common clinic staple ranked near the bottom.
Up to 1 in 5 people with high blood pressure may have a hormone disorder that standard daytime blood tests overlook — because the telltale hormone surges mostly at night.
The survey finding is real. So is the fact that it was commissioned by an organisation that advocates plant-based diets — and the underlying evidence is genuinely mixed.
Menstrual changes, chills, hot flashes. Nobody asked these patients — which is exactly why the answers are interesting, and why they prove nothing.
Adding a coronary calcium score to the AHA’s PREVENT calculator barely moved overall accuracy across 6,000 adults. But in the borderline-risk zone, a high score meant roughly seven times the event rate of a zero.
NICE has declined to recommend Gilead’s lenacapavir for HIV prevention, calling it poor value for money — a decision HIV charities call a missed opportunity to end new infections.
New figures from the World Trade Center Health Program show a sharp jump in certified cancers — a sobering reminder that the health toll of that day is still unfolding, and that survivors, not just responders, are increasingly affected.
In a six-month trial, people with Type 1 diabetes and obesity who ate only between noon and 8 p.m. saw better glucose control than calorie-cutters — with no rise in the dangerous highs and lows that make fasting fraught in this group.
Studies increasingly tie Helicobacter pylori infection to colorectal cancer, but whether treating the bug lowers that risk remains genuinely unsettled.
ARPA-H’s new ADVOCATE program aims to build the first FDA-authorized “agentic” AI that can autonomously help manage heart-failure care — assessing symptoms, ordering labs, even adjusting medications.
A new American Cancer Society–WHO analysis projects annual cancer diagnoses rising from 21 million to 34 million by 2050, driven mostly by aging and population growth — with the heaviest burden falling on poorer countries.
A 15,000-person Swedish study found people with bipolar disorder taking semaglutide had a 21% lower risk of psychiatric hospitalization — an intriguing signal, but not proof, and not seen with every GLP-1 drug.